X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4831) 4831
Book Chapter (40) 40
Dissertation (14) 14
Publication (11) 11
Book Review (6) 6
Conference Proceeding (2) 2
Book / eBook (1) 1
Journal / eJournal (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2407) 2407
hmg-coa reductase (2173) 2173
animals (1364) 1364
statins (1351) 1351
male (1321) 1321
pharmacology & pharmacy (1165) 1165
cholesterol (1004) 1004
female (956) 956
hmg-coa reductase inhibitors (945) 945
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (881) 881
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (878) 878
simvastatin (825) 825
middle aged (703) 703
hmg-coa reductase inhibitor (663) 663
pravastatin (618) 618
biochemistry & molecular biology (595) 595
atorvastatin (589) 589
coenzyme-a reductase (545) 545
aged (520) 520
lovastatin (519) 519
hypercholesterolemia (501) 501
adult (493) 493
rats (489) 489
atherosclerosis (471) 471
cardiac & cardiovascular systems (377) 377
cholesterol - blood (376) 376
lipids (370) 370
inhibitors (348) 348
risk factors (341) 341
peripheral vascular disease (336) 336
mice (327) 327
medicine & public health (324) 324
hypercholesterolemia - drug therapy (317) 317
statin (304) 304
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (294) 294
hydroxymethylglutaryl coa reductases - metabolism (293) 293
low-density-lipoprotein (289) 289
lovastatin - pharmacology (285) 285
coronary-heart-disease (283) 283
metabolism (280) 280
dose-response relationship, drug (277) 277
research (276) 276
anticholesteremic agents - therapeutic use (267) 267
atorvastatin calcium (262) 262
expression (260) 260
cholesterol, ldl - blood (256) 256
in-vitro (256) 256
hydroxymethylglutaryl-coa reductase inhibitors (255) 255
risk (255) 255
cholesterol - metabolism (253) 253
prevention (252) 252
therapy (250) 250
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (247) 247
pharmacology/toxicology (246) 246
oncology (244) 244
simvastatin - pharmacology (240) 240
enzymes (230) 230
drug interactions (229) 229
cells, cultured (228) 228
treatment outcome (227) 227
apoptosis (226) 226
anticholesteremic agents - pharmacology (224) 224
fluvastatin (221) 221
nitric-oxide synthase (218) 218
cell biology (217) 217
hmg coa reductase inhibitors (217) 217
inflammation (213) 213
analysis (210) 210
liver - metabolism (208) 208
cancer (204) 204
inhibitor (200) 200
lipids - blood (199) 199
cholesterol - biosynthesis (195) 195
physiological aspects (194) 194
coa reductase inhibitors (192) 192
hyperlipidemias - drug therapy (192) 192
pravastatin - pharmacology (190) 190
time factors (186) 186
hyperlipidemia (184) 184
cardiovascular diseases (183) 183
inhibition (183) 183
medicine, research & experimental (183) 183
c-reactive protein (182) 182
drug therapy (182) 182
pharmacotherapy (181) 181
enzyme inhibitors - pharmacology (178) 178
health aspects (177) 177
heptanoic acids - pharmacology (177) 177
internal medicine (177) 177
mevalonate pathway (176) 176
triglycerides - blood (175) 175
medicine, general & internal (174) 174
rats, sprague-dawley (173) 173
pyrroles - pharmacology (171) 171
cells (169) 169
antilipemic agents (166) 166
myocardial-infarction (162) 162
cardiovascular disease (160) 160
liver (159) 159
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (158) 158
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4704) 4704
Japanese (126) 126
German (63) 63
French (33) 33
Korean (23) 23
Spanish (12) 12
Russian (8) 8
Chinese (7) 7
Portuguese (6) 6
Czech (2) 2
Slovenian (2) 2
Turkish (2) 2
Italian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Hypertension, ISSN 0194-911X, 08/2007, Volume 50, Issue 2, pp. 377 - 383
Journal Article
Pharmacological reviews, ISSN 1521-0081, 2012, Volume 64, Issue 1, pp. 102 - 146
Journal Article
Journal Article
Circulation research, ISSN 1524-4571, 2017, Volume 120, Issue 1, pp. 229 - 243
The statins have been used for 30 years to prevent coronary artery disease and stroke. Their primary mechanism of action is the lowering of serum cholesterol... 
hydroxymethylglutaryl-CoA reductase inhibitors | rho-associated kinases | cardiovascular diseases | cholesterol, LDL | vascular diseases | CARDIAC & CARDIOVASCULAR SYSTEMS | CoA reductase inhibitors | ACTIVATED RECEPTOR-GAMMA | HIGH-DOSE ATORVASTATIN | NITRIC-OXIDE SYNTHASE | RHO-KINASE-ACTIVITY | HMG-COA REDUCTASE | hydroxymethylglutaryl | ACUTE CORONARY SYNDROMES | RANDOMIZED CONTROLLED-TRIAL | VASCULAR SMOOTH-MUSCLE | HUMAN ENDOTHELIAL-CELLS | LDL | cholesterol | PERIPHERAL VASCULAR DISEASE | PLACEBO-CONTROLLED TRIAL | HEMATOLOGY | Cardiovascular Diseases - physiopathology | Cardiovascular Diseases - drug therapy | Humans | Cholesterol, LDL - antagonists & inhibitors | Cardiovascular System - drug effects | Cardiovascular Diseases - genetics | Cholesterol, LDL - genetics | Cardiovascular System - physiopathology | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Clinical Trials as Topic - methods | Genetic Pleiotropy - genetics | Lipoproteins (low density) | Cell culture | GTP-binding protein | Reactive oxygen species | Cardiovascular disease | Post-translation | Heart diseases | Plaques | Statins | Cardiovascular system | NADPH-diaphorase | Cytokines | Coronary artery | Adenine | Inflammation | Low density lipoprotein | Cholesterol | Nitric-oxide synthase | Rho-associated kinase | Intermediates | Pleiotropy | Molecular modelling | Arteriosclerosis | Nitric oxide | Fibrosis | Hypertrophy
Journal Article
Pharmacology and Therapeutics, ISSN 0163-7258, 2014, Volume 143, Issue 1, pp. 87 - 110
.... The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (HMGCR) is the rate-limiting step in cholesterol biosynthesis and catalyzes the conversion of HMG-CoA to MVA... 
Farnesyl transferase inhibitors | Rho GTPase | Statins | Fibrosis | Asthma | Geranylgeranyl transferase inhibitors | C-REACTIVE PROTEIN | SMALL GTPASE RHOA | BRONCHIAL EPITHELIAL-CELLS | COENZYME-A REDUCTASE | GERANYLGERANYLTRANSFERASE-I INHIBITOR | HMG-COA REDUCTASE | RHO-KINASE INHIBITOR | RANDOMIZED CONTROLLED-TRIAL | PHARMACOLOGY & PHARMACY | SMOOTH-MUSCLE-CELLS | NF-KAPPA-B | rho-Associated Kinases - physiology | rho GTP-Binding Proteins - antagonists & inhibitors | Cardiovascular Diseases - drug therapy | Humans | Alkyl and Aryl Transferases - antagonists & inhibitors | Hydroxymethylglutaryl CoA Reductases - physiology | Lung Diseases - drug therapy | Mevalonic Acid - metabolism | rho GTP-Binding Proteins - physiology | rho-Associated Kinases - antagonists & inhibitors | Neoplasms - drug therapy | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Farnesyltranstransferase - antagonists & inhibitors | Pulmonary Disease, Chronic Obstructive - drug therapy | Enzymes | Hypercholesterolemia | Lung diseases | Physiological aspects | Cardiovascular diseases | Health aspects | Cancer | geranylgeranyl transferase inhibitors | farnesy transferase inhibtors | asthma | fibrosis | cancer | chronic obstructive pulmonary disease
Journal Article
Journal Article
11.